Pulmonary complications in cirrhosis

Current Opinion in Organ Transplantation

Volumn 16, Issue 3, 2011, Pages 281-288

  Sussman, Norman L ^a   Kochar, Rajan ^b   Fallon, Michael B ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NORFLOXACIN; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VARDENAFIL; VASODILATOR AGENT;

ARTICLE; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE SEVERITY; END STAGE LIVER DISEASE; FLUSHING; GENE MUTATION; HEPATOPULMONARY SYNDROME; HUMAN; JAW PAIN; LIVER CIRRHOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG DISEASE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; OXYGEN THERAPY; PATHOGENESIS; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; SCHISTOSOMIASIS MANSONI; SCORING SYSTEM; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT RESPONSE; VASOSPASM;

ANTIHYPERTENSIVE AGENTS; HEMODYNAMICS; HEPATOPULMONARY SYNDROME; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 79958021181     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834664df     Document Type: Article

References (66)

1. Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44:1502-1510. (Pubitemid 44953655)
2. Ramsay MA. Perioperative mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6:451-452.
3. Krowka MJ, Edwards WD. A spectrum of pulmonary vascular pathology in portopulmonary hypertension. Liver Transpl 2000; 6:241-242. (Pubitemid 30174008)
4. Rodriguez-Roisin R, Krowka MJ, Hervé P, Fallon MB, ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24:861-880. (Pubitemid 39504442)
5. Ramsay M. Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol 2010; 23:145-150.
6. Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48:196-203. (Pubitemid 351975544)
7. Roberts KE, Fallon MB, Krowka MJ, et al. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest 2009; 135:1470-1475.
8. Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179:835-842.
9. Pellicelli AM, Barbaro G, Puoti C, et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology 2010; 61:802-806.
10. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996; 17:17-33. (Pubitemid 26100791)
11. Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8:2445-2453.
12. Shapiro M, Scurlock C, Raikhelkar J, et al. Use of inhaled epoprostenol in transition to extubation in a patient after implantation of a ventricular assist device. J Cardiothorac Vasc Anesth 2010; 24:988-989.
13. Melgosa MT, Ricci GL, García-Pagan JC, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl 2010; 16:348-356.
14. Stahler G, von Hunnius P. Successful treatment of portopulmonary hypertension with bosentan: case report. Eur J Clin Invest 2006; 36 (Suppl 3):62-66. (Pubitemid 44179784)
15. Austin MJ, McDougall NI, Wendon JA, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl 2008; 14:287-291. (Pubitemid 351425480)
16. Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011; 139:109-114.
17. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl S):68S-72S. (Pubitemid 38759720)
18. Deibert P, Bremer H, Roessle M, et al. PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension. Eur Respir J 2007; 29:220-221. (Pubitemid 46092023)
19. Cadden IS, Greanya ED, Erb SR, et al. The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation. Ann Hepatol 2009; 8:158-161.
20. Gough MS, White RJ. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl 2009; 15:30-36.
21. Hemnes AR, Robbins IM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl 2009; 15:15-19.
22. Bremer HC, Kreisel W, Roecker K, et al. Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report. J Med Case Reports 2007; 1:46.
23. Ashfaq M, Chinnakotla S, Rogers L, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007; 7:1258-1264. (Pubitemid 46643089)
24. Fix OK, Bass NM, De Marco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007; 13:875-885. (Pubitemid 46939441)
25. Sussman N, Kaza V, Barshes N, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a singlecenter series. Am J Transplant 2006; 6:2177-2182. (Pubitemid 44199553)
26. Bandara M, Gordon FD, Sarwar A, et al. Successful outcomes following living donor liver transplantation for portopulmonary hypertension. Liver Transpl 2010; 16:983-989.
27. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995; 122:521-529.
28. Martinez G, Barberà JA, Navasa M, et al. Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol 1999; 30:882-889. (Pubitemid 29248990)
29. Abrams GA, Jaffe CC, Hoffer PB, et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995; 109:1283-1288.
30. Martinez GP, Barberà JA, Visa J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 2001; 34:651-657. (Pubitemid 32488779)
31. Fuhrmann V, Madl C, Mueller C, et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology 2006; 131:69-75. (Pubitemid 44015748)
32. Regev A, Yeshurun M, Rodriguez M, et al. Transient hepatopulmonary syndrome in a patient with acute hepatitis A. J Viral Hepat 2001; 8:83-86. (Pubitemid 32115918)
33. Teuber G, Teupe C, Dietrich CF, et al. Pulmonary dysfunction in noncirrhotic patients with chronic viral hepatitis. Eur J Intern Med 2002; 13:311-318. (Pubitemid 34812342)
34. Abrams GA, Fallon MB. The hepatopulmonary syndrome. Clin Liver Dis 1997; 1:185-200; xiii.
35. De BK, Sen S, Biswas PK, et al. Hepatopulmonary syndrome in inferior vena cava obstruction responding to cavoplasty. Gastroenterology 2000; 118: 192-196. (Pubitemid 30020387)
36. Gupta D, Vijaya DR, Gupta R, et al. Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol 2001; 96:3395-3399. (Pubitemid 34016666)
37. FallonMB, Krowka MJ, Brown RS, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008; 135:1168-1175.
38. Abrams GA, Sanders MK, Fallon MB. Utility of pulse oximetry in the detection of arterial hypoxemia in liver transplant candidates. Liver Transpl 2002; 8:391-396. (Pubitemid 34467375)
39. Kochar R, Tanikella R, Fallon MB. Serial pulse oximetry in hepatopulmonary syndrome. Dig Dis Sci 2011. [Epub ahead of print]
40. Abrams GA, Nanda NC, Dubovsky EV, et al. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998; 114:305-310. (Pubitemid 28093537)
41. Lee KN, Lee HJ, Shin WW, Webb WR, et al. Hypoxemia and liver cirrhosis (hepatopulmonary syndrome) in eight patients: comparison of the central and peripheral pulmonary vasculature. Radiology 1999; 211:549-553. (Pubitemid 29206829)
42. Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 1996; 17:1-15. (Pubitemid 26100790)
43. Brussino L, Bucca C, Morello M, et al. Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 2003; 362:43-44. (Pubitemid 36835821)
44. Degano B, Mittaine M, Hervé P, et al. Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients. Eur Respir J 2009; 34:138-144.
45. Schenk P, Madl C, Rezaie-Majd S, et al. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000; 133:701-706.
46. Fallon MB, Abrams GA, Luo B, et al. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997; 113:606-614. (Pubitemid 27351790)
47. Ling Y, Zhang J, Luo B, et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology 2004; 39:1593-1602. (Pubitemid 38702660)
48. Carter EP, Hartsfield CL, Miyazono M, et al. Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol 2002; 283:L346-L353. (Pubitemid 34803991)
49. Zhang J, Ling Y, Luo B, et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology 2003; 125:1441-1451. (Pubitemid 37409764)
50. Zhang J, Luo B, Tang L, et al. Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology 2009; 136:1070-1080.
51. Sood et al. [abstract] Hepatology 1998; 282319
52. Robin ED, Laman D, Horn BR, et al. Platypnea related to orthodeoxia caused by true vascular lung shunts. N Engl J Med 1976; 294:941-943.
53. McAdams HP, Erasmus J, Crockett R, et al. The hepatopulmonary syndrome: radiologic findings in 10 patients. AJR Am J Roentgenol 1996; 166:1379-1385. (Pubitemid 26160594)
54. Lima BL, França AV, Pazin-Filho A, et al. Frequency, clinical characteristics, and respiratory parameters of hepatopulmonary syndrome. Mayo Clin Proc 2004; 79:42-48. (Pubitemid 38018583)
55. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005; 41:1122-1129. (Pubitemid 40593920)
56. Song JY, Choi JY, Ko JT, et al. Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics 1996; 97 (6 Pt 1):917-920. (Pubitemid 26170959)
57. Anel RM, Sheagren JN. Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents. Clin Infect Dis 2001; 32:E131-E136.
58. Abrams GA, Fallon MB. Treatment of hepatopulmonary syndrome with Allium sativum L. (garlic): a pilot trial. J Clin Gastroenterol 1998; 27:232-235. (Pubitemid 28495842)
59. Tanikella R, Philips GM, Faulk DK, et al. Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl 2008; 14:1199-1203.
60. Martinez-Palli G, Drake BB, Garcia-Pagan JC, et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 2005; 11:6858-6862. (Pubitemid 43092461)
61. Hovnanian A, Hoette S, Fernandes CJ, et al. Schistosomiasis associated pulmonary hypertension. Int J Clin Pract Suppl 2010; (165):25-28.
62. de Cleva R, Herman P, Pugliese V, et al. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis-prospective study. Hepatogastroenterology 2003; 50:2028-2030. (Pubitemid 37467987)
63. Souza R, Fernandes CJ, Jardim CV. Other causes of PAH (schistosomiasis, porto-pulmonary hypertension and hemolysis-associated pulmonary hypertension). Semin Respir Crit Care Med 2009; 30:448-457.
64. Graham BB, Bandeira AP, Morrell NW, et al. Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 2010; 137 (6 Suppl):20S-29S.
65. Ferreira Rde C, Domingues AL, Markman Filho B, et al. Hepatopulmonary syndrome in patients with Schistosoma mansoni periportal fibrosis. Acta Trop 2009; 111:119-124.
66. Pham DM, Subramanian R, Parekh S. Coexisting hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. J Clin Gastroenterol 2010; 44:e136-e140.